Antibody Responses to Fusobacterium nucleatum Proteins in Prediagnostic Blood Samples are not Associated with Risk of Developing Colorectal Cancer.
Julia ButtMazda JenabMichael PawlitaKim OvervadAnne TjønnelandAnja OlsenMarie-Christine Boutron-RuaultFranck CarbonnelFrancesca Romana ManciniRudolf KaaksTilman KühnHeiner BoeingAntonia TrichopoulouAnna KarakatsaniDomenico PalliValeria Maria PalaRosario TuminoCarlotta SacerdoteSalvatore PanicoBas Bueno-de-MesquitaCarla H van GilsRoel C H VermeulenElisabete WeiderpassJosé Ramón QuirósEric Jeffrey DuellMaria-José SánchezMiren DorronsoroJosé María HouertaEva ArdanazBethany Van GuelpenSophia HarlidAurora Perez-CornagoMarc J GunterNeil MurphyHeinz FreislingDagfinn AuneTim WaterboerDavid J HughesPublished in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2020)
Our findings in prospectively ascertained serum samples contradict the existing literature on the association of F. nucleatum with colorectal cancer risk. Future prospective studies, specifically detecting F. nucleatum in stool or tissue biopsies, are needed to complement our findings.